Gilead 'officially a value stock' after Q1 results, says Piper Jaffray
Piper Jaffray believes Gilead is "officially a value stock" following the company's Q1 results, which the firm calls "one of the most impressive beats in biopharma history." Piper thinks the stock will appeal to value investors and it reiterates an Overweight rating on the name while raising its price target to $106 from $105.